SCHEMBL1707146

SCHEMBL1707146

CCOC(=O)c1coc(COS(C)(=O)=O)n1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 2/20 0.43
NLRP3 Q96P20 1/20 0.40
MAPT P10636 5/20 0.38
ALDH1A1 P00352 4/20 0.38
NPC1 O15118 3/20 0.38
KMT2A Q03164 2/20 0.38
RAB9A P51151 2/20 0.38
MEN1 O00255 1/20 0.38
TP53 P04637 1/20 0.36
XBP1 P17861 1/20 0.36
MAPK1 P28482 1/20 0.36
HTT P42858 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
HSD17B10 Q99714 1/20 0.36
TLR9 Q9NR96 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
FBP1 P09467 1/20 0.36
GLP1R P43220 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.35
HPGD P15428 3/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1166849 0.82 CYP1A2 (0.38) CYP1A2
SCHEMBL2113445 0.81 CYP1A2 (0.46) CYP1A2NLRP3MAPTALDH1A1NPC1
SCHEMBL9714181 0.81 CYP1A2 (0.51) CYP1A2NLRP3MAPTALDH1A1NPC1
SCHEMBL855444 0.79 CYP1A2 (0.50) CYP1A2NLRP3MAPTALDH1A1NPC1
SCHEMBL2070116 0.78 CYP1A2 (0.49) CYP1A2NLRP3MAPTALDH1A1NPC1
SCHEMBL3385122 0.78 CYP1A2 (0.49) CYP1A2NLRP3MAPTALDH1A1NPC1
SCHEMBL861515 0.77 CYP1A2 (0.42) CYP1A2NLRP3MAPTALDH1A1NPC1
SCHEMBL28374254 0.77 CYP1A2 (0.47) CYP1A2NLRP3MAPTALDH1A1NPC1
SCHEMBL160214 0.76 CYP1A2 (0.53) CYP1A2NLRP3MAPTALDH1A1NPC1
SCHEMBL15932112 0.75 CYP1A2 (0.46) CYP1A2NLRP3MAPTALDH1A1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8674111-B2 Oxazole and thiazole derivatives as ALX receptor agonists ACTELION PHARMACEUTICALS LTD. (CH) 2014-03-18 US disclosed
EP-2440536-B1 Oxazole and thiazole derivatives as ALX receptor agonists ACTELION PHARMACEUTICALS LTD (CH) 2013-11-06 EP disclosed
US-20120115916-A1 OXAZOLE AND THIAZOLE DERIVATIVES AS ALX RECEPTOR AGONISTS ACTELION PHARMACEUTICALS LTD. (CH) 2012-05-10 US disclosed
EP-2440536-A1 OXAZOLE AND THIAZOLE DERIVATIVES AS ALX RECEPTOR AGONISTS Actelion Pharmaceuticals Ltd. (CH) 2012-04-18 EP disclosed
WO-2010143158-A1 OXAZOLE AND THIAZOLE DERIVATIVES AS ALX RECEPTOR AGONISTS ACTELION PHARMACEUTICALS LTD (CH) 2010-12-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120115916-A1 OXAZOLE AND THIAZOLE DERIVATIVES AS ALX RECEPTOR AGONISTS P2RX1, GLP1R, P2RX7 CYP1A2 413/4885NLRP3 214/4885MAPT 3232/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.